NABH Approved Hospital
GKNM Hospital > Oncology > Dr.B. Sivanesan
Chairman Department of Oncology & Consultant Medical Oncologist

Dr.B. Sivanesan

MBBS, MD-RT, DM-Medical Oncology, DNB

Doctor Schedule
Mon - Fri10am - 4pm
Specialty
Medical Oncology
Languages
  • English, Tamil

Research Experience

  • Analysis of Risk Factors in Non Insulin Dependent Diabetes Mellitus (1993). This study identified important risks and protective factors in the development of NIDDM. This study was completed in the fourth professional year of the MBBS course under the supervision of Professor M Balasoudarssanane, MD, Department of Preventive & Social Medicine, JIPMER, Pondicherry, India. Unpublished work.
  • Bone Metastasis from Carcinoma Cervix (1998). This retrospective study analyzed the incidence, presentation, distribution, treatment and survival of carcinoma cervix patients who developed bone metastasis. This study was completed in the first year of my residency training. The paper was presented at the VII Annual Conference of Association of Gynecological Oncologists of India at JIPMER, Pondicherry, October1998 and at the XX Annual National Conference of Association of Radiation Oncologists of India at Cuttack, December 1998
  • Comparison of two different Radiotherapy schedules in Multiple Brain Secondaries. (1997 – 1999). This is a prospective study spanning two years. This study was submitted as a dissertation to the TN Dr. MGR Medical University as a mandatory requirement of my residency training in Radiation Oncology. The paper was presented at the XV Annual Conference of Association of Radiation Oncologists of India TN Chapter at Salem, October 1999 and at the XXI Annual National Conference of Association of Radiation Oncologists of India at Calcutta, December 1999
  • Ewing’s Sarcoma: A Madras Medical College Experience: (2001 – 2002). This retrospective study analyzed the incidence, presentation, distribution, treatment and survival of patients with Ewing’s Sarcoma. . This study was completed in the first year of my Medical Oncology training. The paper was presented at the Asia Pacific Musculo Skeletal Society Conference at Chennai 2002
  • Non Small Cell Lung Cancer: A Madras Medical College Experience. (2001 – 2002). This retrospective study analyzed the incidence, presentation, distribution, treatment and survival of patients with NSCLC. This study was completed in the first eighteen months of my Medical Oncology training. The paper was presented at the ISO (Indian Society of Oncology) Conference in 2002 at Mumbai.

 

Clinical Trials

  • A multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of xxxx in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy. Protocol: EFC 6521
  • A Phase II Study to Determine the Safety, Efficacy, and Pharmacokinetics of Multiple Intravenous Doses of xxxx 80 mg, 160 mg, and 320 mg Versus Placebo Administered to Patients with Non-Small Cell Lung Cancer-Related Fatigue and Cachexia
  • A study of Mycobacterium in combination with Paclitaxel plus Cisplatin in Advanced NSCLC Protocol No: CR-60/7260
  • A randomized phase II trial of deforolimus xxxxx compared to progestin in female adult patients with advanced endometrial carcinoma following on line of Protoco AP23573-07-205 l
  • A prospective, non interventional, cohort survey on VTE risk in patients receiving new chemotherapy for cancer.
  • A phase III study of Erbb2 Positive Advanced or Metastatic Gastric or Esophageal or Gastroesophageal junction adenocarcinoma treated with capecitabine plus Oxaliplatin with or without  Drug X
  • Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + Drug X versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously untreated for metastatic disease.
  • A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Verses Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects with Advanced Non-small Cell Lung Cancer.
  • Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients).
  • LUX-Lung 8 (Trial No. 1200.125): A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy. 
  • Observational Follow up for patient who has received BCD-020 (rituximab, CJSC BIOCAD, Russia) / Mabthera for CD20-positive indolent non-Hodgkin lymphoma in BIORIX study
  • A multicenter open-label randomized study of BCD-020 (rituximab, CJSC BIOCAD,Russia) efficacy and safety in comparison with MabThera®(F. Hoffmann-La Roche Ltd ., Switzerland) in monotherapy of CD20-positive indolent non-Hodgkin
  • SADAL: A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • A Multi-center, randomized, double-blind, vehicle-controlled, phase-2 trial to evaluate the efficacy and safety of two concentrations of topical povidone-iodine nail solution (VBP-926) for the treatment of chemotherapy-associated paronychia in cancer patient

Clinical Research and Academic

No Data
dots